baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cyclacel Pharmaceuticals/ US23254L8019 /

2024-06-20 9:22:38 PM	Chg. +0.12	Volume	Bid-	Ask-	High	Low
1.62USD	+8.00%	650 Turnover: 1,053	-Bid Size: -	-Ask Size: -	1.62	1.62

GlobeNewswire 06-04 Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024...

GlobeNewswire 06-03 Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fad...

GlobeNewswire 05-14 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

GlobeNewswire 05-08 Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

GlobeNewswire 05-02 Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Un...

GlobeNewswire 04-30 Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq ...

GlobeNewswire 04-01 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadra...

GlobeNewswire 03-19 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Bu...

GlobeNewswire 03-13 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 03-07 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented...

GlobeNewswire 03-06 Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

GlobeNewswire 02-20 Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

GlobeNewswire 01-30 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

GlobeNewswire 01-08 Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

GlobeNewswire 01-02 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

GlobeNewswire 2023-12-22 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Ma...

GlobeNewswire 2023-12-18 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CD...

GlobeNewswire 2023-12-12 Cyclacel Pharmaceuticals Announces Reverse Stock Split

GlobeNewswire 2023-11-30 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

GlobeNewswire 2023-11-28 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Repor...

GlobeNewswire 2023-11-13 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

GlobeNewswire 2023-11-07 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

GlobeNewswire 2022-03-28 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2022-03-22 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2022-03-09 Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Cyclacel Pharmaceuticals/ US23254L8019 /

If you wish to receive reply to your feedback, please provide your email address.